We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol-Myers Squibb (BMS) inked a pair of collaboration agreements this week — one focused on developing novel cardiovascular disease treatments and the other on domain antibody products.